CagriSema

Description

CagriSema (Cagrilintide + Semaglutide) Acetate Blend

Contents (per vial):

• 5 mg Cagrilintide Acetate
• 5 mg Semaglutide Acetate

Structural Characteristics:
CagriSema combines two long-acting, lipidated incretin and amylin receptor agonists:

• Cagrilintide – a 37-amino acid amylin analog conjugated to a C20 fatty diacid for prolonged albumin binding and extended pharmacokinetics.
• Semaglutide – a 31-amino acid GLP-1 receptor agonist analog with a C18 fatty diacid conjugation, enhancing stability and receptor activity over an extended duration.

This dual-mechanism peptide formulation targets complementary pathways in appetite regulation, glucose control, and metabolic homeostasis.

Mechanism of Action (Research Context):
CagriSema has been investigated for synergistic effects in:

• Weight regulation and obesity research models
• Appetite suppression and satiety signaling
• Glycemic control and insulin sensitivity
• Hepatic fat reduction and metabolic syndrome studies

Synthesis and Quality Control:

• Both peptides manufactured via solid-phase peptide synthesis (SPPS)
• HPLC purified to ≥98%
• Identity confirmed via Mass Spectrometry (MS)

Product Details:

• Form: Lyophilized acetate salt blend
• Appearance: White to off-white powder
• Supplied in: 3mL sterile vial

Solubility & Reconstitution:
Soluble in sterile water, dilute acetic acid, or aqueous buffers at pH 5–7.

• Swirl gently to dissolve; avoid vigorous shaking
• Protect from oxidation and high pH conditions

Storage & Handling:

• Store lyophilized powder at –20°C, away from light and moisture
• After reconstitution, store at 2–8°C for up to 30 days
• For extended storage, aliquot and freeze at –20°C
• Avoid repeated freeze-thaw cycles

Disclaimer:
For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic applications.